In biologics development, a strong scientific idea is only the beginning. A molecule may show compelling biology in discovery, demonstrate good target engagement, and generate early excitement internally or with investors, but none of this guarantees that it can become a safe, manufacturable, and clinically viable therapeutic. That is the reality many early-stage companies face, and it is exactly why early development assessment matters. Early drug development is complex, multidisciplinary, and shaped by interdependent decisions. Data from discovery, drug substance, drug product, immunology, analytics, safety, and regulatory activities must ultimately come together in the first-in-human enabling package. Read this content piece to explore how at Lonza, these connected workstreams are assessed in a coordinated way, helping teams build a more complete and decision-ready foundation for development.
Mazen Noureddin, MD, MHSc, of Houston Methodist Hospital discusses phase 2 data for GSK's once-monthly FGF21 analog efimosfermin presented at The Liver Meeting 2026 and what the findings mean for ongoing phase 3 trials in MASH and compensated cirrhosis.
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
In the first part of a two-part interview, Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center explains which early patient responses led to the dostarlimab study behind Jemperli's rectal cancer approval, and why mismatch repair-deficient tumors are so visible to the immune system.
Updated phase 1 data for micvotabart pelidotin, an antibody-drug conjugate that targets a protein in the tumor extracellular matrix, support Pyxis Oncology’s plan to start a phase 3 trial in recurrent/metastatic head and neck squamous cell carcinoma in mid-2027.
DISCO Pharmaceuticals will receive $40 million upfront, with up to $2.5 billion in potential milestones, to discover bispecific therapeutics for AbbVie that recognize pairs of tumor surface proteins, an approach intended to limit toxicity in healthy tissue.
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.